【MIT CEO x BioSpark】Boston线下活动｜biotech创业和startup公司管理

Jiang He is the scientific co-founder and head of Scientific Affairs in Vizgen, a life science company pioneering in single-cell spatial genomics. He completed his postdoc at MIT, Ph.D. at Harvard University in Xiaowei Zhuang’s lab, and B.S. from University of Science and Technology of China. His work focused on developing single molecule imaging techniques and applying them to study different biological processes. Within Vizgen, Jiang oversees the technology and application development, as well as the lab service division. Jiang has been recognized with numerous awards including Forbes 30 under 30 in Healthcare, Spotlight Scholar at AIF, and STAT Wunderkind awardee.

Tony W. Ho, M.D., is Chief Scientific Officer and Senior Science Partner at Pivotal Bioventure. He was previously Executive Vice President and Head of R&D for CRISPR Therapeutics between 2017 and 2021, responsible for global R&D across all therapeutic areas of the company. During this period, Dr. Ho led and built a world-leading R&D platform with more than 10 product pipelines. Dr. Ho and his team have brought the first CRISPR-based therapy CTX001, three allogeneic CAR-T (CTX110 (CD19), 120 (BCMA), 130 (CD70)), and the first CRISPR edited pancreatic islet progenitor cells (VCTX210, VCTX211) from research bench to the clinic. Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza® (olaparib) and Imfinizi® (durvalumab). Before joining AstraZeneca, Dr. Ho was the head of Neurology and Ophthalmology at Merck, and before Merck, Dr. Ho was the Co-Founder and CSO of Neuronyx.

Dr. Ho received his M.D. from Johns Hopkins University and his B.S. in Electrical Engineering from UCLA. Dr. Ho has published more than 80 papers in a variety of fields and currently serves as an Adjunct Associate Professor of Neurology at the University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.

Dr. X Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical stage immuno-oncology drug development company. GV20 utilizes CRISPR screens and AI approaches to identify novel cancer immunology drug targets, and uses a proprietary AI platform to de novo design fully-human functional antibodies with favorable developability profiles. GV20 is developing these antibodies into immuno-oncology drugs to be tested in the clinic. 

Dr. Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20 in 2022, Dr. Liu has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. She was also the Director of the Center for Functional Cancer Epigenetics at the DFCI and an associate member of the Broad Institute of MIT and Harvard. Her research work focused on algorithm development and data integration modeling for translational cancer research. Her group developed widely used algorithms for modeling transcriptional and epigenetic gene regulation (MACS, Cistrome, MDscan, BETA), analyzing CRISPR screens (MAGeCK), and characterizing tumor immunity (TIMER, TIDE, TRUST). She also contributed to the discovery of cancer drug response biomarkers, drug resistance mechanisms, and effective combination therapies. She has published over 250 peerreviewed papers, and has an H-index of 106. 

Dr. Liu is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Her lab has mentored 25 trainees to independent faculty positions.

Dr. Alan Xu currently is the CEO of MediLink Therapeutics, USA and SVP of Suzhou MediLink Therapeutics. Dr. Xu is responsible for the clinical development of MediLink’s clinical assets, in both China and US. Before joining MediLink, Dr. Xu worked with various MNCs and biotechs in China and US. Dr. Xu holds a Ph.D. from the University of Florida.

Lily Zou is co-founder and CEO of Degron Therapeutics, a biotech company focused on the discovery and development of innovative molecular glue degrader drugs for novel disease targets utilizing it proprietary technology platform. Prior to Degron, Lily was CEO of Fosun Pharma USA and VP of Fosun Pharma Group, where she built and grew Fosun Pharma’s US business with R&D, commercial and investment capabilities, and served as chairman or member of the board of four Fosun portfolio companies, Archimmune Therapeutics, Nature’s Sunshine Products (NASDAQ: NATR), NovelStar and Glycotest. Lily worked at top management consulting firm (Bain & Co.), large pharmas (Novartis, Wyeth, Fosun), and smaller biotechs (ArQule, Coley Pharmaceutical Group) in various functions including BD&L, R&D management, drug discovery, and commercialization. 

Lily holds a Ph.D. in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing University.